Teva Pharmaceutical Industries (TEVA) is down 3.8% today. Here is some analysis on what might have caused this price movement. ([tevapharm.com](https://www.tevapharm.com/news-and-media/latest-news/))
Analysis: There does not appear to be a clear company-specific negative announcement on June 18, 2026, so the pullback may reflect profit-taking after a strong recent run and some caution around Teva’s latest business-development spending. This could also be because investors are weighing the near-term cost of the Emalex acquisition against the longer-term pipeline benefit while the broader market digests a more hawkish interest-rate backdrop. ([tevausa.com](https://www.tevausa.com/news-and-media/press-releases/teva-closes-acquisition-of-emalex-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advanci/?utm_source=openai))
Details:
Sources:
Teva Pharmaceuticals, SEC, Investing.com
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$TEVA Insider Trading Activity
$TEVA insiders have traded $TEVA stock on the open market 27 times in the past 6 months. Of those trades, 0 have been purchases and 27 have been sales.
Here’s a breakdown of recent trading of $TEVA stock by insiders over the last 6 months:
- RICHARD D FRANCIS (President and CEO) has made 0 purchases and 5 sales selling 492,506 shares for an estimated $15,938,289.
- ELIYAHU SHARON KALIF (EVP, Chief Financial Officer) has made 0 purchases and 2 sales selling 452,373 shares for an estimated $15,268,016.
- RICHARD DANIELL (EVP, Europe Commercial) has made 0 purchases and 6 sales selling 237,625 shares for an estimated $7,705,163.
- ERIC A HUGHES (See "Remarks") has made 0 purchases and 4 sales selling 101,572 shares for an estimated $3,281,447.
- MARK SABAG (See "Remarks") sold 62,102 shares for an estimated $1,871,816
- EVAN LIPPMAN (EVP, Business Development) has made 0 purchases and 2 sales selling 41,658 shares for an estimated $1,482,366.
- MATTHEW SHIELDS (EVP, Global Operations) has made 0 purchases and 2 sales selling 33,490 shares for an estimated $1,080,034.
- CHRISTINE FOX (EVP, U.S. Commercial) has made 0 purchases and 2 sales selling 17,022 shares for an estimated $546,302.
- PLACID JOVER (See "Remarks") sold 14,150 shares for an estimated $448,107
- BRIAN SAVAGE (Interim Chief Legal Officer) has made 0 purchases and 2 sales selling 2,401 shares for an estimated $76,916.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$TEVA Hedge Fund Activity
We have seen 322 institutional investors add shares of $TEVA stock to their portfolio, and 291 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NORGES BANK added 33,318,265 shares (+1786.8%) to their portfolio in Q4 2025, for an estimated $1,039,863,050
- WCM INVESTMENT MANAGEMENT, LLC added 26,813,522 shares (+191.4%) to their portfolio in Q1 2026, for an estimated $807,623,282
- GLENVIEW CAPITAL MANAGEMENT, LLC removed 10,032,460 shares (-60.1%) from their portfolio in Q1 2026, for an estimated $302,177,695
- SLATE PATH CAPITAL LP removed 7,927,998 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $247,432,817
- BLACKROCK, INC. added 6,833,776 shares (+11.7%) to their portfolio in Q1 2026, for an estimated $205,833,333
- CAPITAL WORLD INVESTORS added 6,472,554 shares (+274.1%) to their portfolio in Q1 2026, for an estimated $194,953,326
- RUBRIC CAPITAL MANAGEMENT LP removed 6,105,510 shares (-28.6%) from their portfolio in Q1 2026, for an estimated $183,897,961
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$TEVA Analyst Ratings
Wall Street analysts have issued reports on $TEVA in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 04/30/2026
- Barclays issued a "Overweight" rating on 01/30/2026
- Jefferies issued a "Buy" rating on 01/06/2026
- Piper Sandler issued a "Overweight" rating on 12/22/2025
To track analyst ratings and price targets for $TEVA, check out Quiver Quantitative's $TEVA forecast page.
$TEVA Price Targets
Multiple analysts have issued price targets for $TEVA recently. We have seen 9 analysts offer price targets for $TEVA in the last 6 months, with a median target of $42.0.
Here are some recent targets:
- Glen Santangelo from Barclays set a target price of $40.0 on 05/06/2026
- Les Sulewski from Truist Securities set a target price of $45.0 on 04/30/2026
- David Amsellem from Piper Sandler set a target price of $42.0 on 04/30/2026
- Ashwani Verma from UBS set a target price of $42.0 on 04/30/2026
- Chris Schott from JP Morgan set a target price of $40.0 on 04/30/2026
- Jason Gerberry from B of A Securities set a target price of $42.0 on 04/09/2026
- Matt Dellatorre from Goldman Sachs set a target price of $45.0 on 02/09/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
